|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00385203 |
To determine the anti-tumour activity and biological effects of AZD2171 at a dose of 45mg, primarily in GIST patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic STS resistant to standard therapy.
Condition | Intervention | Phase |
Gastrointestinal Stromal Tumors Soft Tissue Sarcomas |
Drug: AZD2171 |
Phase II |
MedlinePlus related topics: | Cancer Soft Tissue Sarcoma |
Drug Information available for: | Imatinib Imatinib mesylate Cediranib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171 as Measured by FDG-PET Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate |
Estimated Enrollment: | 25 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | August 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom | |||||
Research Site | |||||
Sutton, United Kingdom | |||||
Research Site | |||||
Manchester, United Kingdom |
AstraZeneca |
Study Director: | Emerging Oncology Medical Science Director, MD | AstraZeneca |
Astrazeneca Information - outside of the US 
  |
Study ID Numbers: | D8480C00046 |
First Received: | October 5, 2006 |
Last Updated: | December 15, 2007 |
ClinicalTrials.gov Identifier: | NCT00385203 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
|